Taiho Oncology, Inc.

This study is testing a combination of two drugs, ASTX727 and venetoclax, in adults with acute myeloid leukemia (AML) who are 75 or older or have health issues that make standard strong chemotherapy too risky. The goal is to see if the combination is safe and effective at control…

This study tests a new combination of drugs (futibatinib plus standard immunotherapy) in adults with advanced esophageal or pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination shrinks tumors and is safe. About 53 people will take part, and t…

This study is for people with advanced or metastatic cancer who are already taking the drug futibatinib and benefiting from it. The goal is to keep giving them the drug while closely watching for side effects over a longer period. About 15 participants will join this rollover stu…

This study tests whether adding the drug zipalertinib to standard chemotherapy after lung cancer surgery helps prevent the cancer from returning. It is for people with early-stage (IB-IIIA) non-small cell lung cancer that has specific uncommon EGFR mutations. About 360 participan…

This study tests an experimental drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow disease progression. About 253 adults will take…

This study tests whether adding the experimental drug zipalertinib to standard chemotherapy helps people with a specific type of advanced lung cancer (EGFR exon 20 insertion) live longer without their cancer growing. About 285 adults who have not had prior treatment for their adv…

This study tested a new drug combination (tolinapant plus decitabine/cedazuridine) in 33 people with a rare and aggressive blood cancer called peripheral T-cell lymphoma that had come back or not responded to prior treatment. The goal was to find a safe dose and see if the combin…

This study provides continued treatment with the oral drug ASTX727 for adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in an earlier trial. The main goal is to gather long-term safety informatio…

This program gives patients with advanced bile duct cancer that has a specific FGFR2 gene change access to the drug futibatinib. It is for people who have tried standard treatments without success or cannot tolerate them. The goal is to provide a treatment option when others have…